Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 4/20 | 0.86 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.86 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.86 |
| ▸ | GMNN | O75496 | 2/20 | 0.86 |
| ▸ | LMNA | P02545 | 2/20 | 0.86 |
| ▸ | TP53 | P04637 | 2/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.86 |
| ▸ | MAPT | P10636 | 2/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.86 |
| ▸ | BLM | P54132 | 2/20 | 0.86 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.86 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.86 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.86 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.86 |
| ▸ | HPGD | P15428 | 1/20 | 0.86 |
| ▸ | THPO | P40225 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ic261 SCHEMBL3697594 | 0.92 | CSNK1D (1.00) | CSNK1DCSNK1A1MAPK1CSNK1EGMNN | |
| Ic261 SCHEMBL29467414 | 0.92 | CSNK1D (1.00) | CSNK1DCSNK1A1MAPK1CSNK1EGMNN | |
| Ic261 SCHEMBL2786157 | 0.92 | CSNK1D (1.00) | CSNK1DCSNK1A1MAPK1CSNK1EGMNN | |
| Ic261 SCHEMBL905701 | 0.92 | CSNK1D (1.00) | CSNK1DCSNK1A1MAPK1CSNK1EGMNN | |
| SCHEMBL5464438 | 0.80 | CSNK1D (0.78) | CSNK1DCSNK1A1MAPK1CSNK1EGMNN | |
| SCHEMBL5464433 | 0.80 | CSNK1D (0.78) | CSNK1DCSNK1A1MAPK1CSNK1EGMNN | |
| SCHEMBL5469713 | 0.80 | MDM2 (1.00) | CSNK1DCSNK1A1MAPK1CSNK1EGMNN | |
| SCHEMBL14448889 | 0.80 | MDM2 (1.00) | CSNK1DCSNK1A1MAPK1CSNK1EGMNN | |
| SCHEMBL5469718 | 0.80 | MDM2 (1.00) | CSNK1DCSNK1A1MAPK1CSNK1EGMNN | |
| SCHEMBL5472398 | 0.79 | CSNK1D (0.71) | CSNK1DCSNK1A1MAPK1CSNK1EGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PFIZER INC | 2006-11-09 | — | — | US | disclosed |
| US-6906093-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1509224-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003097044-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030176487-A1 | 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | SUGEN, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-6469032-B2 | MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION; ANTICARCINOGENIC, -DIABETIC, -PROLIFERATIVE AND -INFLAMMATORY AGENTS; VASCULAR SYSTEM DISORDERS | SUGEN, INC. | 2002-10-22 | — | — | US | disclosed |
| US-20020102608-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2002-08-01 | — | — | US | disclosed |
| US-20010027207-A1 | 3-(4'-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | TANG PENG CHO (US) | 2001-10-04 | — | — | US | disclosed |
| US-6225335-B1 | MODULATES TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION; FOR THERAPY OF CANCER, ATHEROSCLEROSIS, ARTHRITIS AND RESTENOSIS AND METABOLIC DISEASES SUCH AS DIABETES | SUGEN, INC. | 2001-05-01 | — | — | US | disclosed |
| EP-0934931-A2 | 3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators | Sugen, Inc. (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0769947-A4 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN INC (US) | 1998-09-30 | — | — | EP | disclosed |
| EP-0769947-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | Sugen, Inc. (US) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996040116-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027207-A1 | 3-(4'-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | ERBB2, MKI67, ABL1 | CSNK1D 516/4885CSNK1A1 282/4885MAPK1 472/4885 |
| US-20030176487-A1 | 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | ERBB2, MKI67, ABL1 | CSNK1D 516/4885CSNK1A1 282/4885MAPK1 472/4885 |
| US-20020102608-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | PTPRJ, ERBB2, JAK2 | CSNK1D 788/4885CSNK1A1 253/4885MAPK1 725/4885 |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | CSNK1D 1229/4885CSNK1A1 659/4885MAPK1 4185/4885 |
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGES3 | CSNK1D 1331/4885CSNK1A1 752/4885MAPK1 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.